Form 4: Xeris Biopharma Executive Acquires Shares and Stock Appreciation Rights

Kevin McCulloch, President and COO of Xeris Biopharma Holdings, acquired 150,000 shares of common stock and 200,000 stock appreciation rights on August 1, 2024.

Summary

• On August 1, 2024, Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., acquired 150,000 shares of common stock at $0.
• Following the transaction, McCulloch directly owns 1,601,953 shares of common stock.
• McCulloch also acquired 200,000 stock appreciation rights (SARs) with an exercise price of $2.43, which vest on September 1, 2026.
• The SARs will be settled in cash upon exercise.
• Following the transaction, McCulloch directly owns 200,000 SARs.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares by an executive could be seen as a slightly positive signal, but without additional context, it's difficult to gauge the overall impact.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a positive signal about the executive's confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's valuation and future performance.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the specifics of these transactions (size, type, executive level) are often compared to industry peers.
• For example, similar biotech companies like Amgen or Gilead Sciences also have executives who regularly report stock transactions via Form 4 filings.
• The size of the acquisition and the type of instrument (stock vs. options/SARs) can be benchmarked against industry averages for executive compensation and ownership.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the executive.
• There is no immediate impact on employees, customers, suppliers, or creditors.

Key Dates